Setting the Standard for Advanced Health
Advancing regenerative science through umbilical cord–derived mesenchymal stem cells and exosome-based technologies.
Human umbilical cord tissue–derived mesenchymal stem cells (hUC-MSCs) represent a promising frontier in regenerative science, offering unique immunomodulatory properties and paracrine-mediated support for tissue homeostasis.
Our cGMP-compliant cell products are ethically sourced from full-term human umbilical cords in the United States, rigorously tested for safety, purity, and potency, and validated through IRB-approved research protocols.
Low MHC class I expression and absence of MHC class II molecules make hUC-MSCs suitable for allogeneic applications. Cytokines, growth factors, and extracellular vesicles enriched with microRNAs mediate intercellular communication and support tissue regeneration through paracrine mechanisms.
cGMP Human Umbilical Cord Derived MSCs
Ethically Sourced Tissue
Our MSCs are sourced from ethically donated, full-term human umbilical cords in the United States, obtained from suppliers certified by the American Association of Tissue Banks (AATB).
95%+ Viability
Viability testing assesses the health, integrity, and functionality of cells. Our partner lab minimum benchmark is 80%—but we commonly achieve a higher rate of about 95%, verified through automated cell counters.
cGMP Compliant
All cell preparation and handling occurs in a US-based laboratory that is FDA-registered and cGMP-compliant, ensuring the identity, strength, quality, and purity of our mesenchymal stem cell product.
Immune Privileged
hUC-MSCs exhibit low expression of MHC class I molecules and absence of MHC class II molecules on their surface, allowing them to avoid recognition by CD4+ T lymphocytes and prevent T cell activation.
MSCs do not transfer or propagate their own DNA in recipients. Their benefits are mediated through transient survival and paracrine mechanisms of action.
“After incorporating hUC-MSC protocols into our practice, we have observed remarkable improvements in joint function and mobility among our patients. The science behind this approach is compelling.”
“Working with United Regenerative has been transformative for my recovery journey. Issues that had been limiting my performance for years have resolved significantly.”
“The quality of biologics and the rigor of their research protocols set United Regenerative apart. I confidently recommend their services to colleagues and patients alike.”
“The transparency and compliance standards at United Regenerative are unmatched. Their commitment to IRB-approved protocols gives us confidence in every partnership.”
“Our athletes have experienced meaningful improvements in recovery timelines. The quality of the cell product and the scientific rigor behind it speak for themselves.”
Dr. Marc Funderlich Jr.
Functional & Regenerative Medicine Director
A physician innovator enrolled in the Regenerative and Stem Cell Technologies Program at Johns Hopkins University. Academic focus includes stem cell biology, gene editing, immunotherapy, and translational regenerative medicine.
Integrates clinical experience with cutting-edge research in cell therapy, exosome engineering, and FDA-compliant protocols.
We work with clinics, practices, and researchers across the country.
Partner with us for wholesale distribution, clinical consultation, or research collaboration.